



Pliant Therapeutics to Present Data at The Liver Meeting® 2020

November 9, 2020

SOUTH SAN FRANCISCO, Calif., Nov. 9, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced a poster presentation at The Liver Meeting® 2020 hosted by the American Association for the Study of Liver Diseases (AASLD) to be held virtually November 13 – 16, 2020.



Details for the poster presentation at The Liver Meeting are as follows:

Poster Title: [Profiling Fibrosis Regression in a Rat Model of Non-Alcoholic Steatohepatitis](#) (Abstract #0321)

Session: Basic Fibrosis Research and Stellate Cell Biology

Time/Date: Friday, November 13, 2020: 6:00 AM – 11:55 PM EDT

The presentation is available to registered participants via the [AASLD 2020 website](#). The poster will be available on the Pliant Therapeutics website, under the "Our Science" section, at www.pliantrx.com on November 13.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of $\alpha_v\beta_6$ and $\alpha_v\beta_1$ integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of $\alpha_v\beta_1$ for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on [Twitter](#), [LinkedIn](#), and [Facebook](#).

Investor Contact:

Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
<mailto:ir@pliantrx.com>

Media Contact:

Cambria Fuqua
Canale Communications
cambria.fuqua@canalecomm.com

View original content to download multimedia: <http://www.prnewswire.com/news-releases/pliant-therapeutics-to-present-data-at-the-liver-meeting-2020-301168419.html>

SOURCE Pliant Therapeutics, Inc.